That wasn't the scope of the study.
This was the scope.
As it is the first clinical investigation of the Company’s MagSense® technology the study was designed to be
a small proof-of-principle study with the primary objective of achieving an initial assessment of the safety
and tolerability of the MagSense® injectable imaging agent. A secondary objective of the study is the
confirmation that the route of administration is effective in allowing the imaging agent to reach the patient’s
lymph nodes.
Ann: First-in-human Study Progress Update, page-62
-
- There are more pages in this discussion • 134 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
